MorphoSys (ETR:MOR) received a €86.00 ($102.38) price objective from investment analysts at Goldman Sachs Group in a note issued to investors on Thursday. The firm presently has a “neutral” rating on the stock. Goldman Sachs Group’s price objective would indicate a potential downside of 5.81% from the company’s previous close.
Several other brokerages have also recently commented on MOR. Oddo Bhf set a €90.00 ($107.14) target price on MorphoSys and gave the stock a “buy” rating in a report on Tuesday, February 20th. Berenberg Bank set a €103.00 ($122.62) target price on MorphoSys and gave the stock a “buy” rating in a report on Tuesday, May 15th. JPMorgan Chase & Co. set a €100.00 ($119.05) target price on MorphoSys and gave the stock a “buy” rating in a report on Thursday, May 17th. Royal Bank of Canada set a €58.00 ($69.05) target price on MorphoSys and gave the stock a “sell” rating in a report on Wednesday, May 2nd. Finally, Bryan, Garnier & Co set a €91.00 ($108.33) target price on MorphoSys and gave the stock a “buy” rating in a report on Monday, April 9th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of €86.36 ($102.81).
Shares of ETR:MOR opened at €91.30 ($108.69) on Thursday. MorphoSys has a 12 month low of €49.63 ($59.08) and a 12 month high of €88.10 ($104.88).
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.